Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634185 | 0.91 | HRH3 (0.50) | HRH3L3MBTL1DPP4MAPTSMN1; SMN2 | |
| SCHEMBL13634230 | 0.87 | HRH3 (0.55) | HRH3L3MBTL1DPP4MAPTSMN1; SMN2 | |
| SCHEMBL13634292 | 0.83 | HRH3 (0.52) | HRH3L3MBTL1DPP4MAPTSMN1; SMN2 | |
| SCHEMBL10278217 | 0.82 | HRH3 (0.48) | HRH3L3MBTL1DPP4SMN1; SMN2RAB9A | |
| SCHEMBL10136842 | 0.81 | HRH3 (0.49) | HRH3L3MBTL1DPP4SMN1; SMN2RAB9A | |
| SCHEMBL13634266 | 0.80 | HRH3 (0.46) | HRH3MAPTSMN1; SMN2RAB9AOGA | |
| SCHEMBL13634296 | 0.80 | HRH3 (0.49) | HRH3L3MBTL1DPP4MAPTSMN1; SMN2 | |
| SCHEMBL13999708 | 0.79 | HRH3 (0.42) | HRH3MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13634365 | 0.78 | HRH3 (0.47) | HRH3L3MBTL1DPP4MAPTSMN1; SMN2 | |
| SCHEMBL3435877 | 0.78 | HRH3 (0.52) | HRH3SMN1; SMN2RAB9AOGANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HRH3 338/4885L3MBTL1 3267/4885DPP4 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.